Close Menu

NEW YORK (GenomeWeb) – OmniSeq and Laboratory Corporation of America have extended their exclusive distribution agreement for OmniSeq's immune profiling and pan-cancer next-generation sequencing tests the companies signed in 2017.

As part of the expanded deal, LabCorp will distribute OmniSeq's Advance and OmniSeq MSI NGS tests. The original deal covered the OmniSeq Comprehensive and Immune Report Card clinical assays.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Jan
28
Sponsored by
Sophia Genetics

This webinar discusses how the University of Michigan has implemented a new next-generation sequencing (NGS) capture-based solution to assess myeloid malignancies while minimizing required laboratory resources. 

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
22
Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.